We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Shares of RHHBY opened at $39.25 on Thursday ... Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after acquiring an additional 344 shares in the last quarter.

We believe that this was related to stock-outs of other products included in the market definition, primarily [indiscernible]. To account for this, the Q3 values were restated to improve accuracy.

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy ...